Evaluation of adjuvant effects of fucoidan for improving vaccine efficacy.
10.4142/jvs.2015.16.2.145
- Author:
Su Yeon KIM
1
;
Hong Gu JOO
Author Information
1. Laboratory of Veterinary Pharmacology, College of Veterinary Medicine, Jeju National University, Jeju 690-756, Korea. jooh@jejunu.ac.kr
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
antigen-specific antibody;
fucoidan;
spleen cells;
vaccine adjuvant;
vaccine antigen
- MeSH:
Adjuvants, Immunologic/pharmacology;
Animals;
Antigens, Bacterial/*immunology;
Bacterial Vaccines/administration & dosage/*immunology;
Biomarkers/metabolism;
Bordetella bronchiseptica/*immunology;
Cells, Cultured;
Cytokines/*metabolism;
Female;
Flow Cytometry;
Fucus/*chemistry;
Gene Expression Regulation/drug effects;
Mice;
Mice, Inbred BALB C;
Mycoplasma hyopneumoniae/*immunology;
Polysaccharides/*pharmacology;
Spleen/metabolism
- From:Journal of Veterinary Science
2015;16(2):145-150
- CountryRepublic of Korea
- Language:English
-
Abstract:
Fucoidan is a sulfated polysaccharide derived from brown seaweed, including Fucus vesiculosus. This compound is known to have immunostimulatory effects on various types of immune cells including macrophages and dendritic cells. A recent study described the application of fucoidan as a vaccine adjuvant. Vaccination is regarded as the most efficient prophylactic method for preventing harmful or epidemic diseases. To increase vaccine efficacy, effective adjuvants are needed. In the present study, we determined whether fucoidan can function as an adjuvant using vaccine antigens. Flow cytometric analysis revealed that fucoidan increases the expression of the activation markers major histocompatibility complex class II, cluster of differentiation (CD)25, and CD69 in spleen cells. In combination with Bordetella bronchiseptica antigen, fucoidan increased the viability and tumor necrosis factor-alpha production of spleen cells. Furthermore, fucoidan increased the in vivo production of antigen-specific antibodies in mice inoculated with Mycoplasma hyopneumoniae antigen. Overall, this study has provided valuable information about the use of fucoidan as a vaccine adjuvant.
